Programmheft

Sitzung

47 - Young Investigator Meeting
Young Investigator Meeting
4. November 2022, 13:00 - 14:00, Gartensaal 2

Abstract

Quality of warfarin anticoagulation in adults with short bowel syndrome on home parenteral nutrition
R. Fumagalli1, M. Szlaszynska1, M. Di Nisio2, S. Barco1, Presenter: R. Fumagalli1 (1Zürich, 2Chieti)

Objective
Patients with short bowel syndrome and nutritional deficiency necessitate long-term home parenteral nutrition (HPN). Thromboembolic complications in patients on HPN have an annual incidence of about 12%, whereas the prevalence is at least 50%. There is no firm evidence on optimal anticoagulation for HPN patients. Vitamin K antagonists (VKA) remain the most widely used drug class in this patient group. In light of the substantial paucity of data on quality of VKA anticoagulation in adults on HPN, its safety and effectiveness are uncertain.
Methods
This retrospective cohort study included adult patients on long-term HPN managed at a university hospital (2004-2015). HPN patients on warfarin therapy were matched based on sex, age, and indication for anticoagulation to controls also on warfarin. We compared time in therapeutic range (TTR) of therapeutic-dosed warfarin treatment (INR range 2.0-3.0) between the two groups and assessed thrombotic and bleeding events. Incidence rates of were calculated as number of events/100 patient-years. Ethical approval was obtained.
Results
12 patients on HPN and 96 control patients were included. Median follow-up time was 48 (Q1–Q3: 23–89) months for HPN patients and 30 (Q1– Q3 19–43) months for controls. Overall, median TTR calculated over the entire follow-up period of warfarin anticoagulation was 62% (Q1–Q3: 47–73) in HPN patients and 68% (Q1–Q3: 55–78) in controls. The incidence of a composite of thromboembolic, major bleeding, and anticoagulation-related death events was similar in both groups with an incidence ratio of 0.9 (95% CI: 0.2–3.0) events per 100 patient-years. Only one patient from controls died for an intracerebral hemorrhage.
Conclusion
VKA anticoagulation can be adequately managed in HPN patients and is associated to a low rate of complications.
Für statistische Zwecke und um bestmögliche Funktionalität zu bieten, speichert diese Website Cookies auf Ihrem Gerät. Das Speichern von Cookies kann in den Browser-Einstellungen deaktiviert werden. Wenn Sie die Website weiter nutzen, stimmen Sie der Verwendung von Cookies zu.